Publications

Seminal Scientific Publications

1983
“Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti.” The first description of the syndrome in a tropical developing country. The New England Journal of Medicine 309:945-50.

1985
“The acquired immunodeficiency syndrome in Haiti.” Identified the role of contaminated blood transfusions early in the HIV epidemic in Haiti. Annals of Internal Medicine 103:674-8.

1986
“Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immunodeficiency syndrome.” Described isosporiasis in AIDS patients and the effectiveness of trimethoprim-sulfamethoxazole in therapy and prevention of recurrence. The New England Journal of Medicine 315:87-90.

1989
“Treatment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syndrome.” Established the efficacy of trimethroprim-sulfamethoxazole in initial therapy and prophylaxis of cyclosporiasis and isosporiasis. The New England Journal of Medicine 320:1044-7.

1993
“Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection.” Determined that isoniazid prevents tuberculosis and delays the progression of HIV infection to disease in symptomatic HIV persons. The Lancet 342:268-72.

1996
“Heterosexual transmission of HIV in Haiti.” Described the dramatic shift in HIV transmission in Haiti from blood transfusions and men who have sex with men to the general population. Annals of Internal Medicine 125:324-30.

2000
“Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomized trial.” Documented the high rate of tuberculosis recurrence after therapy in patients with AIDS and the value of post-treatment secondary prophylaxis. The Lancet 356:1470-4.

2000
“Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients.” Established ciproflaxin as acceptable therapy for patients with cyclosporiasis and isosporiasis who cannot tolerate trimethoprim-sulfamethoxazole. Annals of Internal Medicine 132:885-8.

2002
“Comprehension during informed consent in a less-developed country.” Evaluated comprehension during the informed consent process and made recommendations for improvement in developing country settings. The Lancet 360:1301-2.

2003
“Decreased congenital syphilis incidence in Haiti’s rural Artibonite Region following decentralized prenatal screening.” Described improved program for syphilis screening and treatment for pregnant women to prevent congenital syphilis. The American Journal of Public Health 93:444-6.

2005
“Antiretroviral therapy in a thousand patients with AIDS in Haiti.” Reported GHESKIO’s experience treating the first 1,000 AIDS patients with outcomes comparable to US clinics. The New England Journal of Medicine 353:2325-34.

2007
“Antiretroviral therapy for HIV-1-infected children in Haiti.” Reported efficacy and feasibility of delivering pediatric antiretroviral therapy in Haiti. The Journal of Infectious Diseases 195:1396-8.

2007

“Cost-Effectiveness of Rapid Syphilis Screening in Prenatal HIV Testing Programs in Haiti.” Schackman BR, Neukermans, CP, Fontain, SN, Nolte C, Joseph P, Pape JW, Fitzgerald DW.  Plos Medicine 2007; 4:e183.

2009

“Five-year Survival of Patients with AIDS Receiving Antiretroviral Therapy in Haiti.” Leger P, Charles Macarthur, Severe P, Riviere C, Beauharnais Carole Anne, Koenig S, Miller E, Johnson WD Jr., Pape JW, Fitzgerald DW. The New England Journal of Medicine. 2009; 361:828-829.

2010

“Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti.” Severe P, Jean Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick R, Johson W, Pape JW, Fitzgerald D. The New England Journal of Medicine 2010; 363:257-265.

2011

Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti.” Koenig S P., Bang H, Severe P, Jean Juste MA, Ambroise A, Edwards A, Hippolyte J, Fitzgerald D W., McGreevy J, Riviere C, Marcelin S, Secours R, Johnson W D., Pape JW, Schackman B R.  PloS Medicine 2011; 8:9.

2011

“Timing of antiretroviral therapy for HIV-1 infection and tuberculosis” Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. The New England Journal of Medicine 2011; 365:1482-91.

2012

“Oral cholera vaccine and integrated cholera control in Haiti. Ivers L, Pape JW, Farmer P.  The Lancet. 2012 Jun 2; 379(9831):2026-8.

2013

Cost-Effectiveness of Early Versus Standard Antiretroviral Therapy in HIV-Infected Adults in Haiti. Koenig SP, Bang H, Severe P, Jean Juste MA, Ambroise A, Edwards A, Fitzgerald D, Riviere C, Secours R, Johnson WDJ, Pape JW, Schackman B (2011) PLoS Medicine 2013 8(9): e1001095. 

2014

“Embracing Oral Cholera Vaccine: the Shifting response to cholera.” Pape JW and Rouzier V. The New England Journal of Medicine 2014; 370;22;2067-2069

2016

“Ten-year survival of patients with AIDS receiving antiretroviral therapy in Haiti”. Pierre S, Jamat-Khat D, Pape JW, Fitzgerald D, McNairy ML. The New England Journal of Medicine 2016 Jan 28; 374(4):397-8.

2017

“Same-Day HIV Testing with Initiation of Antiretroviral Therapy versus Standard Care for Persons Living with HIV: a Randomized Unblinded Trial.” Koenig S, Dorvil N, .Dévieux J, Hedt-Gauthier B, Riviere C, Faustin M, Lavoile K, Perodin C, Apollon A, Duverger L, McNairy M, Kelly A, Hennessey, KA, Souroutzidis A, Cremieux PY, Severe P, Pape JW   PLoS Medicine 2017 Jul 25;14(7):e1002357. 

 

The estimated population of Haiti is 11.1 million people.

1983

GHESKIO has received uninterrupted funding from the NIH since 1983.

A COMMUNITY ORGANIZATION

"The community knows us for the last 33 years. They know it's their institution."

Three Pillars

The three pillars for us, for development, are health, education, and economic opportunities. Its really global health in action!